{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pityriasis-rosea/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"44c5742e-2d6e-5ce6-806a-03940c5572f8","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field 61ab21bf-31b5-4e95-a548-fbf9e6d3f670 --><h2>When should I suspect pityriasis rosea?</h2><!-- end field 61ab21bf-31b5-4e95-a548-fbf9e6d3f670 -->","summary":"","htmlStringContent":"<!-- begin item 0ba529c5-cd4a-4c85-b9fe-d1cd65d1a829 --><!-- begin field bb362198-3f00-41fb-b027-7f54112f8162 --><ul><li><strong>Suspect pityriasis rosea in a person presenting with skin lesions with the following features </strong>(images are available at <u><a href=\"http://www.dermnetnz.org/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"4f53d989-4b1a-4a12-8b17-ab7d009ccbee\">www.dermnetnz.org</a>):</u><ul><li><strong>Appearance of individual lesions:</strong><ul><li>Multiple, discrete, pink-red ('salmon coloured') or fawn coloured.</li><li>Flat or slightly raised.</li><li>Circular or oval, and typically 0.5–1 cm in diameter.</li><li>Usually slightly scaly — the centre tends to clear leaving the classical appearance of peripheral 'collarette' scaling around the edge of the lesion.</li><li>The lesions are not vesicular and do not tend to occur on palmar or plantar skin surfaces.</li></ul></li><li><strong>Distribution of lesions:</strong><ul><li>The rash is usually symmetrical.</li><li>Most lesions occur on the trunk and proximal limbs, with few (usually less than 10%) distal to the mid-upper arm and mid-thigh.</li><li>On the trunk, lesions occur along the lines of cleavage parallel to the ribs (forming a 'Christmas tree' pattern on the upper back and V-shaped pattern on the upper chest) and are distributed transversely across the lower abdomen and lower back.</li><li>The face and scalp may be involved in children.</li></ul></li></ul></li><li><strong>Pityriasis rosea typically starts with a 'herald patch' that appears before the generalized eruption, although this may not always be present.</strong><ul><li>The interval between the appearance of the herald patch and the more widespread rash is usually 5–15 days but can be shorter or longer.</li><li>The herald patch is usually larger than subsequent lesions (typically 2–5 cm in diameter, occasionally much larger), well defined, round or oval, erythematous, and slightly raised, with the same 'collarette' of scale at the margin as seen in subsequent lesions. It usually occurs on the trunk, thigh, upper arm, or neck but can appear anywhere on the body.</li></ul></li><li><strong>Be aware that: </strong><ul><li>Atypical forms of pityriasis rosea can occur and include:<ul><li>Inverse pityriasis rosea — extremities are predominantly affected with relative sparing of the trunk.</li><li>Pityriasis (rosea) circinata et marginata of Vidal — few large patches that are often localized and may persist for several months.</li><li>Pityriasis gigantean — lesions are larger and fewer.</li><li>Pustular, purpuric, haemorrhagic, vesicular, papular, or urticarial lesions.</li></ul></li><li>Itch may be present.</li><li>An upper respiratory tract infection may precede the rash. Systemic symptoms are usually absent during the generalized rash stage.</li></ul></li><li><strong>Consider whether the rash may be caused by </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/pityriasis-rosea/diagnosis/differential-diagnosis/\">another condition</a></strong> <strong> such as HIV or secondary syphilis.</strong><ul><li>Arrange further investigation/referral as appropriate — see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a> and <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/\">Syphilis</a> for more information.</li></ul></li><li><strong>Reconsider the diagnosis of pityriasis rosea if the generalized rash persists for longer than 12 weeks. </strong></li></ul><!-- end field bb362198-3f00-41fb-b027-7f54112f8162 --><!-- end item 0ba529c5-cd4a-4c85-b9fe-d1cd65d1a829 -->","topic":{"id":"c96d68c3-bb0b-5b8c-b256-6b3e415d7ab2","topicId":"76763692-46bc-4f1e-add3-6c012ccd584a","topicName":"Pityriasis rosea","slug":"pityriasis-rosea","lastRevised":"Last revised in April 2020","chapters":[{"id":"82c04d82-7b6f-594a-8190-44f70c341f1b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b21af5b-81ad-5b28-9df9-d6b7c4fdd3d4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"357337fc-eefc-5ff8-84bf-cc4e15f9a2da","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67565f4b-e371-5339-8d04-8fb65cb26c28","slug":"changes","fullItemName":"Changes"},{"id":"3b3d1372-8e27-5563-9a36-273677bd9a82","slug":"update","fullItemName":"Update"}]},{"id":"75f5c2f6-34b3-5b64-ab41-c7457b8eedd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26135976-eb67-5dd8-ad15-9a98086871b7","slug":"goals","fullItemName":"Goals"},{"id":"96f6df37-1ba4-5020-8435-cbeac8de1488","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"026de696-4951-5e10-a246-456d67c1fea8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"03d26d2a-90f8-53c5-97e9-cff9d95ae299","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87a8200e-6cd0-588d-8d4b-86117be364e6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ba1ef82b-8a8a-558d-a84a-552083dcd2e1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a8f04415-38ec-5eb9-8282-733c37db5bac","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"38f858f2-48f8-54e6-bb01-5b58106435cc","slug":"definition","fullItemName":"Definition"},{"id":"f7fffe58-e2a4-5913-8a5a-354aad8d52f0","slug":"causes","fullItemName":"Causes"},{"id":"090f1bfe-2513-53a8-ade3-e8368ec7d5d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"20025f23-bbb9-5095-9acc-da8d9e15840b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"72d63a33-0ca6-552f-81a8-200eef91d046","slug":"complications","fullItemName":"Complications"}]},{"id":"75dd0d1f-b162-54b6-b1ba-3833b13ae73e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"44c5742e-2d6e-5ce6-806a-03940c5572f8","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f2c8da26-1065-5bb2-add8-43b39f41b5fe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d71093b6-b130-5eeb-8e0f-443adf8be4aa","fullItemName":"Management","slug":"management","subChapters":[{"id":"0bc06d9c-42f1-5228-adf5-4eda9826e67a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c48f4302-0f7c-58d9-86ad-d5379d244e71","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"eee3f004-1425-502e-a455-287742b3ec77","slug":"emollients","fullItemName":"Emollients"},{"id":"51eb73bd-9e63-5028-815d-bf148fa863d9","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"186fab77-8c30-557b-bd7b-f756eb8f9cab","slug":"antihistamines","fullItemName":"Antihistamines"}]},{"id":"b3c2db78-1290-58fb-9bb3-3a5db8e45669","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e683b047-2b38-5f72-a4b8-c79a83946894","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2d6d1b8c-ffc1-59d1-89f5-a5abdf200635","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27361c81-c185-5b67-b396-0305d0519609","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45051d9e-ec60-5c2c-b5ba-3144fa01ed3b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4e570021-eea5-51d7-a0b9-52d2862efb98","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"259f8083-da67-544d-b6f7-dbb776d27e96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4c25a2fe-3c87-5ac4-b4c3-7f8e41ff3c06","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"75dd0d1f-b162-54b6-b1ba-3833b13ae73e","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"23fdca73-f92b-5c4a-ad4e-2152bb95df74","slug":"basis-for-recommendation-a27","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field adbafc5e-8bb8-410b-9405-8422c42bbe0a --><h3>Basis for recommendation</h3><!-- end field adbafc5e-8bb8-410b-9405-8422c42bbe0a -->","summary":null,"htmlStringContent":"<!-- begin item a271f7c1-3de4-431a-b466-db28eaaa6139 --><!-- begin field 8b827bd9-5163-4dfb-96f2-325972437a4c --><p>The recommendations on when to suspect pityriasis rosea are based on clinical guidance <em>Pityriasis rosea</em> from the Primary Care Dermatology Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">PCDS, 2018</a>], a position statement from the European Academy of Dermatology and Venereology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh, 2016</a>], a Cochrane review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Contreras‐Ruiz, 2019</a>], expert opinion in a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Stirling, 2010</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh and Zawar, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Drago, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Urbina, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Rodriguez-Zuniga, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Villalon-Gomez, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Y&uuml;ksel, 2019</a>].</p><ul><li>The recommendation on syphilis testing is based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">PCDS, 2018</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Chuh et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Trayes, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Y&uuml;ksel, 2019</a>].</li><li>The recommendation to consider HIV testing is pragmatic — rash associated with HIV seroconversion can present similarly to pityriasis rosea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-rosea/references/\">Zawar et al, 2010</a>].</li></ul><!-- end field 8b827bd9-5163-4dfb-96f2-325972437a4c --><!-- end item a271f7c1-3de4-431a-b466-db28eaaa6139 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}